As a seasoned healthcare policy analyst who has spent the last decade tracking the intricate dance between federal regulators and private insurers, I have watched the Medicare Advantage landscape transform through various cycles of expansion and contraction. Today, we find ourselves at a pivotal moment where the Centers for Medicare & Medicaid Services (CMS) has significantly tightened the requirements for quality ratings. The 2027 Star Ratings data, which was recently released, reveals a stark divide between industry giants who managed to pivot their clinical operations and those who have been blindsided by methodological shifts. This conversation explores the dramatic recovery of major payers, the precarious financial position of regional players, and the cascading effects these scores have on the millions of seniors relying on these plans for their daily medical care.
We examine the high-stakes volatility of the 2027 Star Ratings, focusing on how certain insurers orchestrated nearly unprecedented comebacks while others faced catastrophic declines in their high-rated membership. The discussion delves into the technical adjustments CMS implemented, including the introduction of new quality measures and the raising of thresholds, which have collectively lowered the industry’s average rating. We also analyze the multi-billion dollar financial implications for the 2028 payment year and how these administrative shifts are forcing carriers to cut supplemental benefits, potentially destabilizing the coverage options available to the aging population.
Humana recently saw its membership in plans rated four stars or higher jump from 41% to a staggering 93% for 2027. What strategic shifts or internal pressures allowed them to pull off such a massive recovery after consecutive years of decline?
It was truly a high-stakes, do-or-die moment for the Kentucky-based payer after they watched their enrollment in high-performing plans collapse to just 20% in 2026. To move from that historic low back up to 93% in a single year indicates a massive, company-wide mobilization to align their clinical and administrative operations with the exact metrics CMS now prioritizes. By successfully pushing their largest contract back above the 4-star cutoff, they have essentially secured a financial lifeline that could net them $3 billion or more in extra revenue when payments are adjusted in 2028. This recovery is a vital “clear win” for a company that has been under intense pressure from unexpectedly high medical spending and skeptical investors. When the news hit, the market’s relief was palpable, sending their stock soaring nearly 13% in postmarket trading as it became clear the insurer had followed through on its promise to resuscitate its margins.
In sharp contrast to that success, Alignment Healthcare saw its high-rated membership plummet from 98% down to just 25% for 2027. What does this signify for the viability of mid-sized or regional insurers in an increasingly difficult regulatory environment?
This is a devastating setback for a California-based insurer that manages coverage for about 280,000 members across five states. Losing the 4-star status on a contract that accounts for three-fourths of their total membership is not just a branding problem; it is a financial crisis that could result in a revenue loss of over $170 million in 2028. The immediate 20% drop in their share price reflects a deep concern that smaller players may lack the diversified portfolio needed to absorb such a localized ratings hit. Their leadership, led by figures like Dawn Maroney, is already signaling a move toward litigation, suggesting that the CMS methodology does not accurately reflect their performance and warrants a rigorous legal review. This mirrors a growing trend where insurers, feeling the pressure of “moving goalposts,” are increasingly turning to the courts to challenge the administrative remedies provided by the government.
CMS has tweaked its methodology for the 2027 ratings by adding new measures and raising the thresholds for quality scores. How are these technical changes reshaping the competitive landscape for the industry’s largest carriers?
The agency is effectively raising the bar for what constitutes a high-quality plan, utilizing up to 43 different measures that now carry more weight or have higher benchmarks for success. We’ve seen the average star rating, when weighted by enrollment, dip to 3.99 from 4.01, while the number of prestigious 5-star contracts fell from 22 in 2026 down to just 15 for 2027. For giants like UnitedHealth and CVS, these shifts resulted in manageable but notable reductions in their high-star enrollment, even as they remain at the higher end of the spectrum compared to their peers. Interestingly, we saw a few other winners like Blue Cross Blue Shield of Michigan and Devoted Health join Humana in improving their standings, while five of the top ten insurers saw their numbers slip. This environment has turned the star ratings into a primary theater of competition, where even minor administrative tweaks can shift billions of dollars in bonuses and rebates between companies.
With average star ratings falling and major insurers like UnitedHealth and CVS seeing double-digit percentage drops in high-rated enrollment, how will this ultimately affect the benefits and premiums for seniors?
The reality for beneficiaries is becoming increasingly tumultuous as we head into the open enrollment period starting October 15. Because star ratings are directly tied to the lucrative bonuses and rebates that insurers use to fund “extra” benefits, any drop in scores typically forces companies to protect their margins by cutting supplemental offerings. We are entering what looks like a third consecutive year of pullbacks, with major carriers narrowing their physician networks, increasing cost-sharing, and even terminating plans in certain counties. In fact, more than 3 million seniors are currently in plans that were either terminated or have exited their local markets, meaning they will be forced to hunt for new coverage options. This trend suggests that the era of “rich” benefit packages, filled with zero-dollar premiums and expansive dental or vision coverage, is being curtailed as insurers grapple with shrinking profits and higher quality bars.
What is your forecast for the Medicare Advantage market as we look toward the 2028 payment adjustments?
I anticipate a period of intense financial divergence where the “star-power” of an insurer dictates its entire growth strategy and market stability. Humana’s projected $3 billion revenue boost in 2028 will give them a massive war chest to reinvest in benefits, likely allowing them to aggressively poach members from competitors who are currently reeling from ratings downgrades. At the same time, the trend of litigation will likely accelerate; as we saw with Clover Health’s successful suit that forced a recalculation of 2026 stars, insurers now view the courtroom as a legitimate tool for reclaiming lost quality points. For the average senior, the market will likely feel more volatile and less predictable, with fewer 5-star options available and a greater emphasis on basic medical necessity over the flashy supplemental perks that defined the early 2020s. Ultimately, the industry is shifting toward a “quality-first” model where clinical performance is no longer a goal, but a prerequisite for financial survival.
